Drug penetration in solid tumours

[1]  S. Ametamey,et al.  Ionizing Radiation Antagonizes Tumor Hypoxia Induced by Antiangiogenic Treatment , 2006, Clinical Cancer Research.

[2]  Limor Chen,et al.  Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. , 2006, Cancer research.

[3]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[4]  Wilson Mok,et al.  Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. , 2006, Cancer research.

[5]  I. Tannock,et al.  Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration , 2006, British Journal of Cancer.

[6]  A. Minchinton,et al.  Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  I. Tannock,et al.  The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. , 2006, Cancer research.

[8]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[9]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[10]  I. Tannock,et al.  Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy , 2005, Clinical Cancer Research.

[11]  Neil Desai,et al.  Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[13]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[14]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[15]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[16]  W. Wilson,et al.  Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. , 2005, Journal of medicinal chemistry.

[17]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[18]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[19]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[20]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[21]  Janet E. Husband,et al.  Imaging in Oncology , 2004 .

[22]  A. Minchinton,et al.  Microregional Effects of Gemcitabine in HCT-116 Xenografts , 2004, Cancer Research.

[23]  A. Minchinton,et al.  Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture , 2004, Cancer Research.

[24]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[25]  W. Wilson,et al.  Oxygen Dependence of the Metabolic Activation and Cytotoxicity of Tirapazamine: Implications for Extravascular Transport andActivity in Tumors , 2004, Radiation research.

[26]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[27]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[28]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[29]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[30]  W. Denny,et al.  Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. , 2003, Cancer research.

[31]  Helen E. Burston,et al.  Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. , 2003, Cancer research.

[32]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[33]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[34]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[35]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[36]  R. Jain,et al.  Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells , 2002, British Journal of Cancer.

[37]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[38]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[39]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Oloumi,et al.  Identification of genes differentially expressed in V79 cells grown as multicell spheroids , 2002, International journal of radiation biology.

[42]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[43]  W. Wilson,et al.  Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. , 2001, The Journal of pharmacology and experimental therapeutics.

[44]  M. Wientjes,et al.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. , 2001, The Journal of pharmacology and experimental therapeutics.

[45]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[47]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[48]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[49]  I. Tannock,et al.  The influence of expression of P‐glycoprotein on the penetration of anticancer drugs through multicellular layers , 2000, International journal of cancer.

[50]  R K Jain,et al.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.

[51]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[52]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  I. Tannock,et al.  Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  K. Hicks,et al.  Measurement of extravascular drug diffusion in multicellular layers. , 1999, British journal of cancer.

[55]  B. Dubray,et al.  Reproducibility of measurements of potential doubling time of tumour cells in the multicentre National Cancer Institute protocol T92-0045 , 1999, British Journal of Cancer.

[56]  M. Dewhirst,et al.  Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. , 1998, International journal of radiation oncology, biology, physics.

[57]  W. Wilson,et al.  Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. , 1998, International journal of radiation oncology, biology, physics.

[58]  R. Kerbel,et al.  Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. , 1998, Cancer letters.

[59]  M C Weissler,et al.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. , 1998, Cancer research.

[60]  A. Fyles,et al.  Interstitial fluid pressure in cervical carcinoma , 1998, Cancer.

[61]  P. Loadman,et al.  Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. , 1998, British Journal of Cancer.

[62]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[63]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[65]  R. Schwendener,et al.  Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer , 1998, European Journal of Clinical Pharmacology.

[66]  M. Manfait,et al.  Characterization of Acidic Vesicles in Multidrug-resistant and Sensitive Cancer Cells by Acridine Orange Staining and Confocal Microspectrofluorometry , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[67]  H. Hollema,et al.  Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy. , 1997, British Journal of Cancer.

[68]  R. Jain,et al.  Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.

[69]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[70]  R. Kerbel,et al.  Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. , 1996, Human cell.

[71]  K. Hicks,et al.  Multicellular membranes as an in vitro model for extravascular diffusion in tumours. , 1996, The British journal of cancer. Supplement.

[72]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[73]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.

[74]  W. Panje,et al.  In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non‐involved mucosa of head and neck region , 1995, Cell proliferation.

[75]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[76]  D. Kerr,et al.  Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[78]  P. Olive,et al.  Drug and radiation resistance in spheroids: cell contact and kinetics , 1994, Cancer and Metastasis Reviews.

[79]  R. Milroy,et al.  A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. , 1993, British Journal of Cancer.

[80]  G. Rosner,et al.  Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. , 1993, Microvascular research.

[81]  J. Brown,et al.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. , 1993, British Journal of Cancer.

[82]  P. Workman,et al.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. , 1993, British Journal of Cancer.

[83]  B. Teicher,et al.  Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[84]  R. Jain,et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.

[85]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[86]  M. Dewhirst,et al.  Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. , 1992, Radiation research.

[87]  G. Aherne,et al.  Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining. , 1992, British Journal of Cancer.

[88]  P. Noker,et al.  Diversity of penetration of anti‐cancer agents into solid tumours , 1991, Cell proliferation.

[89]  K. Väänänen,et al.  Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. , 1991, Biochimica et biophysica acta.

[90]  D. Chaplin,et al.  Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. , 1990, British Journal of Cancer.

[91]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[92]  I. Tannock,et al.  Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.

[93]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[94]  A. Begg,et al.  Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. , 1987, Cancer research.

[95]  V. Marks,et al.  Immunocytochemical localisation of VP16-213 in normal and malignant tissues. , 1987, Cancer letters.

[96]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[97]  F. Buchegger,et al.  Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. , 1987, Cancer research.

[98]  D. Chaplin,et al.  Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.

[99]  R. Durand.  Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. , 1986, Journal of the National Cancer Institute.

[100]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[101]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[102]  D. Chaplin,et al.  Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. , 1985, British Journal of Cancer.

[103]  C. Erlichman,et al.  Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. , 1984, Cancer research.

[104]  J. Denekamp,et al.  Endothelial-cell proliferation in experimental tumours. , 1982, British Journal of Cancer.

[105]  MANUAL OF SYMBOLS, EQUATIONS & DEFINITIONS IN PHARMACOKINETICS , 1982, Journal of clinical pharmacology.

[106]  R. Durand.  Use of Hoechst 33342 for cell selection from multicell systems. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[107]  R. Durand.  Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. , 1981, Cancer research.

[108]  S. Ohkuma,et al.  Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages , 1981, The Journal of cell biology.

[109]  J. Carlsson,et al.  Penetration of substances into tumor tissue—A methodological study on cellular spheroids , 1981, In Vitro.

[110]  E. Wibe.  Resistance to vincristine of human cells grown as multicellular spheroids. , 1980, British Journal of Cancer.

[111]  R. Weichselbaum,et al.  Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. , 1980, Cancer research.

[112]  J. Doroshow,et al.  Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. , 1979, Cancer research.

[113]  R. Sutherland,et al.  Resistance to adriamycin in multicellular spheroids. , 1979, International journal of radiation oncology, biology, physics.

[114]  D. Hirst,et al.  TUMOUR CELL PROLIFERATION IN RELATION TO THE VASCULATURE , 1979, Cell and tissue kinetics.

[115]  I. Tannock,et al.  Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.

[116]  N. Bachur,et al.  Cytofluorescence localization of adriamycin and daunorubicin. , 1974, Cancer Research.

[117]  I. Tannock,et al.  THE RELATION BETWEEN CELL PROLIFERATION AND THE VASCULAR SYSTEM IN A TRANSPLANTED MOUSE MAMMARY TUMOUR , 2007 .

[118]  B. Sylvén,et al.  On the Access of Blood-Borne Dyes to Various Tumour Regions , 1962, British Journal of Cancer.

[119]  W. Bottomley,et al.  A Kinin in Apple Fruitlets , 1959, Nature.

[120]  B. Sylvén,et al.  A Rapid Method for studying Tumour Blood Supply using Systemic Dyes , 1959, Nature.

[121]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[122]  R. Durand.  Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? , 2008, Cancer Chemotherapy and Pharmacology.

[123]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  D. Kerr,et al.  Aspects of cytotoxic drug penetration, with particular reference to anthracyclines , 2004, Cancer Chemotherapy and Pharmacology.

[125]  J. Carlsson,et al.  Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids , 2004, Cancer Chemotherapy and Pharmacology.

[126]  P. Noker,et al.  Variability of tumor response to chemotherapy II. Contribution of tumor heterogeneity , 2004, Cancer Chemotherapy and Pharmacology.

[127]  John E. Moulder,et al.  Tumor hypoxia: its impact on cancer therapy , 2004, Cancer and Metastasis Reviews.

[128]  Jörgen Carlsson,et al.  Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids , 2004, Cancer Chemotherapy and Pharmacology.

[129]  D. Grahame-Smith.  Preclinical toxicological testing and safeguards in clinical trials , 2004, European Journal of Clinical Pharmacology.

[130]  R. Gillies,et al.  Microenvironmental and cellular consequences of altered blood flow in tumours. , 2003, The British journal of radiology.

[131]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[132]  I. Tannock,et al.  Factors that influence the penetration of methotrexate through solid tissue , 2001, International journal of cancer.

[133]  P. Carmeliet,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[134]  A. Minchinton,et al.  Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model , 1999, Cancer Chemotherapy and Pharmacology.

[135]  K. Clow,et al.  Multilayers of cells growing on a permeable support. An in vitro tumour model. , 1997, Acta oncologica.

[136]  J. Brown,et al.  NCI's anticancer drug screening program may not be selecting for clinically active compounds. , 1997, Oncology research.

[137]  P. Hunter,et al.  An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. , 1997, British Journal of Cancer.

[138]  J. Babich,et al.  Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. , 1991, Progress in clinical and biological research.

[139]  R. Jain,et al.  Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. , 1991, Cancer research.

[140]  M. Trotter,et al.  Evidence for intermittent radiobiological hypoxia in experimental tumour systems. , 1989, Biomedica biochimica acta.

[141]  D. Kerr,et al.  Cytotoxic drug penetration studies in multicellular tumour spheroids. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[142]  R. Durand.  Variable radiobiological responses of spheroids. , 1980, Radiation research.

[143]  R. Jain,et al.  Mass transport in tumors: characterization and applications to chemotherapy. , 1980, Advances in cancer research.

[144]  J. Gross,et al.  Dynamics of microvascular flow in implanted mouse mammary tumours. , 1977, Bibliotheca anatomica.

[145]  Durand Re,et al.  Radiation response of multicell spheroids--an in vitro tumour model. , 1976 .

[146]  R. Sutherland,et al.  Radiation response of multicell spheroids--an in vitro tumour model. , 1976, Current topics in radiation research quarterly.

[147]  I. Tannock,et al.  The proliferation of capillary endothelial cells. , 1972, Cancer research.

[148]  John Crank,et al.  The Mathematics Of Diffusion , 1956 .